Comparative Pharmacology
Head-to-head clinical analysis: PENTACEF versus ZEVTERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENTACEF versus ZEVTERA.
PENTACEF vs ZEVTERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Ceftobiprole, the active moiety of ZEVTERA, is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in methicillin-resistant Staphylococcus aureus (MRSA), leading to cell death.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
400 mg intravenously every 8 hours
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 10-20 hours in severe impairment (CrCl <10 mL/min); dosing adjustment required for CrCl <50 mL/min.
Terminal elimination half-life is approximately 3.5 hours in patients with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life extends to ~6 hours, requiring dose adjustment.
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-20% biliary/fecal elimination.
Approximately 70% of the dose is excreted unchanged in urine, with 20% recovered in feces via biliary elimination. Minor route: <5% as metabolites.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic